Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The technology, developed by Katalin Karikó and Drew Weissman, also holds promise for HIV vaccines and cancer treatment.
A boost in protection is needed to offset the persistent disparities in the toll of COVID between racial and ethnic groups.
People at lower risk may not need an updated booster, but without a CDC recommendation, insurance companies wouldn’t have to cover it.
People ages 6 months and older are eligible for new Moderna and Pfizer-BioNTech boosters targeting XBB.1.5 omicron variant.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
Vaccine type, older age, male sex and especially smoking were associated with lower antibody responses.
People 65 and older and immunocompromised people can get a second bivalent booster; most unvaccinated people now need only one initial shot.
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
Updated boosters could go to the “worried well” who have good insurance rather than to those at highest risk.
NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.
An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.
New vaccine approach triggers neutralizing antibody production and T-cell responses and lowers risk of infection.
People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.